Reduce GMP Audit Risk in Hazardous Pharmaceutical Environments

In pharmaceutical projects, problems rarely arise because explosion protection is ignored. They arise because it is handled in isolation.

Typical consequences:

• Late engineering changes
• Increased validation effort
• Audit findings and documentation gaps
• Production delays and costly retrofits

Key insight

Most risks are not technical failures – they are integration, design, and lifecycle issues.

This guide helps QA, Validation, and Engineering teams evaluate EX solutions from a GMP and audit perspective.

You will learn:

• Typical GMP and audit risks related to explosion protection
• Why zoning decisions impact validation and documentation
• How cleaning and hygienic design affect inspection outcomes
• What inspectors actually look for in EX environments
• Key criteria for selecting GMP-ready EX solutions
• Practical examples from pharmaceutical production

We focus on:

• Clear decision criteria
• Pharma-specific zoning insights
• Inspector-focused guidance
• Practical use cases
• Structured Readiness Check

This Buyer’s Guide is intended for professionals involved in:

• Quality Assurance & Compliance
• Validation & Qualification
• CSV / Data Integrity
• Engineering & Technical Operations
• Procurement & Project Management
• OEM machine builders for pharma

Most EX resources focus only on certification and protection concepts. This guide focuses on:

• GMP compliance and audit readiness
• Validation and lifecycle considerations
• Cleanability and hygienic design
• Real-world pharmaceutical challenges

Helping you avoid revalidation, audit findings, and project delays.